EP1617804A4 - IMPROVED VACCINES BASED ON THERMAL SHOCK PROTEINS AND IMMUNOTHERAPIES THEREOF - Google Patents

IMPROVED VACCINES BASED ON THERMAL SHOCK PROTEINS AND IMMUNOTHERAPIES THEREOF

Info

Publication number
EP1617804A4
EP1617804A4 EP04759338A EP04759338A EP1617804A4 EP 1617804 A4 EP1617804 A4 EP 1617804A4 EP 04759338 A EP04759338 A EP 04759338A EP 04759338 A EP04759338 A EP 04759338A EP 1617804 A4 EP1617804 A4 EP 1617804A4
Authority
EP
European Patent Office
Prior art keywords
immunotherapies
heat shock
shock protein
improved heat
based vaccines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04759338A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1617804A2 (en
Inventor
Jessica Baker Flechtner
Kenya Prince-Cohane
Sunil Mehta
Paul Slusareqicz
Sofija Andjelic
Brian H Barber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agenus Inc
Original Assignee
Antigenics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/776,521 external-priority patent/US7420037B2/en
Priority claimed from US10/820,067 external-priority patent/US7309491B2/en
Application filed by Antigenics LLC filed Critical Antigenics LLC
Publication of EP1617804A2 publication Critical patent/EP1617804A2/en
Publication of EP1617804A4 publication Critical patent/EP1617804A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6043—Heat shock proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/622—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP04759338A 2003-04-11 2004-04-09 IMPROVED VACCINES BASED ON THERMAL SHOCK PROTEINS AND IMMUNOTHERAPIES THEREOF Withdrawn EP1617804A4 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US46246903P 2003-04-11 2003-04-11
US46374603P 2003-04-18 2003-04-18
US50341703P 2003-09-16 2003-09-16
US10/776,521 US7420037B2 (en) 2003-02-13 2004-02-12 Heat shock protein-based vaccines and immunotherapies
PCT/US2004/004340 WO2004071457A2 (en) 2003-02-13 2004-02-13 Improved heat shock protein-based vaccines and immunotherapies
US10/820,067 US7309491B2 (en) 2003-04-11 2004-04-08 Heat shock protein-based vaccines and immunotherapies
PCT/US2004/010983 WO2004091493A2 (en) 2003-04-11 2004-04-09 Improved heat shock protein-based vaccines and immunotherapies

Publications (2)

Publication Number Publication Date
EP1617804A2 EP1617804A2 (en) 2006-01-25
EP1617804A4 true EP1617804A4 (en) 2007-07-25

Family

ID=35539709

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04759338A Withdrawn EP1617804A4 (en) 2003-04-11 2004-04-09 IMPROVED VACCINES BASED ON THERMAL SHOCK PROTEINS AND IMMUNOTHERAPIES THEREOF

Country Status (8)

Country Link
EP (1) EP1617804A4 (pt)
JP (1) JP2007525448A (pt)
KR (1) KR20050121721A (pt)
AU (1) AU2004229458B2 (pt)
BR (1) BRPI0409321A (pt)
CA (1) CA2521809A1 (pt)
MX (1) MXPA05010881A (pt)
WO (1) WO2004091493A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8541002B2 (en) * 2003-09-12 2013-09-24 Agenus Inc. Vaccine for treatment and prevention of herpes simplex virus infection
CN101448517A (zh) 2005-04-19 2009-06-03 伊莱利利公司 用于疾病免疫干预的单价和多价合成多糖抗原
CY1112212T1 (el) * 2008-04-24 2015-12-09 Immatics Biotechnologies Gmbh Νεα σκευασματα πεπτιδιων που σχετιζονται με ογκους τα οποια συνδεονται σε μορια του αντιγονου ανθρωπινων λευκοκυτταρων (hla) ταξης i ή ii για εμβολια
PL2113253T3 (pl) * 2008-04-30 2010-09-30 Immatics Biotechnologies Gmbh Nowa postać leku - preparat zawierający peptydy nowotworowe wiążące się z antygenami ludzkich leukocytów klasy I i II, zastosowany w szczepionce
CN103687616A (zh) * 2011-07-21 2014-03-26 生物技术工具公司 Dnak制剂
US10568948B2 (en) * 2015-05-13 2020-02-25 Agenus Inc. Vaccines for treatment and prevention of cancer
MA52363A (fr) 2018-04-26 2021-03-03 Agenus Inc Compositions peptidiques de liaison à une protéine de choc thermique (hsp) et leurs méthodes d'utilisation

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997006821A1 (en) * 1995-08-18 1997-02-27 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
WO1999022761A1 (en) * 1997-10-31 1999-05-14 Sloan-Kettering Institute For Cancer Research Conjugate heat shock protein-binding peptides
WO2001078772A1 (en) * 2000-04-17 2001-10-25 Mojave Therapeutics Inc. Heat shock protein-based antiviral vaccines
WO2003062262A2 (en) * 2001-12-26 2003-07-31 Mojave Therapeutics, Inc. Modulation of heat-shock-protein-based immunotherapies
WO2004071457A2 (en) * 2003-02-13 2004-08-26 Antigenics, Inc. Improved heat shock protein-based vaccines and immunotherapies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9202219D0 (en) * 1992-02-03 1992-03-18 Connaught Lab A synthetic heamophilus influenzae conjugate vaccine

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997006821A1 (en) * 1995-08-18 1997-02-27 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
WO1999022761A1 (en) * 1997-10-31 1999-05-14 Sloan-Kettering Institute For Cancer Research Conjugate heat shock protein-binding peptides
WO2001078772A1 (en) * 2000-04-17 2001-10-25 Mojave Therapeutics Inc. Heat shock protein-based antiviral vaccines
WO2003062262A2 (en) * 2001-12-26 2003-07-31 Mojave Therapeutics, Inc. Modulation of heat-shock-protein-based immunotherapies
WO2004071457A2 (en) * 2003-02-13 2004-08-26 Antigenics, Inc. Improved heat shock protein-based vaccines and immunotherapies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2004091493A2 *

Also Published As

Publication number Publication date
BRPI0409321A (pt) 2006-05-23
MXPA05010881A (es) 2006-05-31
JP2007525448A (ja) 2007-09-06
WO2004091493A2 (en) 2004-10-28
EP1617804A2 (en) 2006-01-25
AU2004229458A1 (en) 2004-10-28
CA2521809A1 (en) 2004-10-28
KR20050121721A (ko) 2005-12-27
AU2004229458B2 (en) 2009-11-19
WO2004091493A3 (en) 2006-04-20

Similar Documents

Publication Publication Date Title
EP1804831A4 (en) VACCINES BASED ON LLO AND LISTERIA
PL1673460T3 (pl) Szczepionki rekombinowane i ich zastosowanie
ZA200603882B (en) Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides
IL223457A0 (en) Flavivirus vaccines
EP1679966A4 (en) BENZIMIDAZOLE-, BENZTRIAZOLE- AND BENZIMIDAZOLONE-SUBSTITUTED O-GLUCOSIDES
AU2003239932A8 (en) Tetravalent dengue vaccines
IL174397A0 (en) 7-amino alkylidenyl-heterocyclic quinolones and naphthyridones
IL218269A0 (en) Dna-vaccines encoding heat shock proteins
HK1088837A1 (en) Clk-peptide and slk-peptide
EP1622563A4 (en) IMPROVED VACCINES AND IMMUNOTHERAPIES BASED ON THERMAL SHOCK PROTEIN
GB0405834D0 (en) Item authentication
IL161870A0 (en) Sub-calibre projectile
GB0212046D0 (en) Vaccines
EP1617804A4 (en) IMPROVED VACCINES BASED ON THERMAL SHOCK PROTEINS AND IMMUNOTHERAPIES THEREOF
EP1687327A4 (en) NOVEL POLYPEPTIDES ASSOCIATED WITH THERMAL SHOCK PROTEIN 20 AND USES THEREOF
EP1692456A4 (en) SELF-SHOOTING STOREY
GB0328753D0 (en) Hepatitis B vaccines
GB0316910D0 (en) Fluorocombretastatin and derivatives thereof
EP1675493A4 (en) IMPROVED FOOD HANDLING METHODS
AU2003237701A8 (en) Vaccines
GB2408795B (en) Oven-racks and ovens including them
GB0317376D0 (en) Immunogenic protein and uses thereof
TW572198U (en) Smoke bomb
GB2400170B (en) An open-fire effect gas fired inset heater
AU2003268252A8 (en) Tick polypeptides as anticoagulants and vaccines

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20051110

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL HR LT LV MK

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 2/00 20060101ALI20060705BHEP

Ipc: C07K 4/00 20060101ALI20060705BHEP

Ipc: A61K 39/00 20060101AFI20060705BHEP

PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

A4 Supplementary search report drawn up and despatched

Effective date: 20070627

17Q First examination report despatched

Effective date: 20081208

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BARBER, BRIAN, H.

Inventor name: ANDJELIC, SOFIJA

Inventor name: SLUSAREQICZ, PAUL

Inventor name: MEHTA, SUNIL

Inventor name: PRINCE-COHANE, KENYA

Inventor name: FLECHTNER, JESSICA, BAKER

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20101030